Erwan Mortier
Mortier, Erwan, 1976-
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 203996914 (Personal)
Permalink: http://viaf.org/viaf/203996914
Preferred Forms
-
100 0 _
‡a
Erwan Mortier
-
100 1 _
‡a
Mortier, Erwan,
‡d
1976-
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells |
|
| IL-15 trans-presentation promotes human NK cell development and differentiation in vivo |
|
| IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation |
|
| IL-15Rα membrane anchorage in either cis or trans is required for stabilization of IL-15 and optimal signaling |
|
| [Cut the cord, you're ready to set off on your own!] |
|
| Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor. |
|
| Design, synthesis and evaluation of small molecule inhibitors of the interleukin (IL)-15 system. |
|
| Développement de nouveaux antagonistes de l'interleukine-15 |
|
| Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization |
|
| The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha |
|
| Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. |
|
| Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease |
|
| Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway. |
|
| [Interleukin 2 revival: a revisited model and new therapeutic applications] |
|
| Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets |
|
| Mechanistic and Structural Insights on the IL-15 System through Molecular Dynamics Simulations |
|
| Molecular and functionnal characterisation of a natural human soluble form of the interleukin-15 receptor alpha chain. |
|
| Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist |
|
| NK Cell Hyporesponsiveness: More Is Not Always Better |
|
| Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering |
|
| RLI et agonistes, enjeux pour la thérapie anti-cancéreuse |
|
| Rôle de la coupure protéolytique du récepteur de l'Interleukine-15 dans la régulation de la trans-présentation : implication du complexe IL-15.IL-15Rα soluble en thérapie |
|
| The Soluble Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer |
|
| Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins |
|
| Syndecan-1 regulates the biological activities of interleukin-34. |
|
